Velban
(vinblastine sulfate)Phase 3Small molecule
Vinblastine sulfate is a chemotherapy drug used to treat various cancers including lymphomas, testicular cancer, and breast cancer by stopping cancer cells from dividing and growing.[1] Velban is currently being investigated across 26 indications[3], with its most advanced program in Phase 3.[1]
Velban is one of 552 small molecule programs targeting Glioma. It is currently in Phase 3.
26
Indications
55
Total Trials
8
Active Trials
551
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 26 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Velban
EEastern Cooperative Oncology Group
Phase 3
Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Norvir
AbbViePreclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma15 trials
Show 12 more trials
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
Unknown status·MMount Vernon Cancer Centre at Mount Vernon Hospital·Phase 3·NCT00041210·850 enrolled
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00005584·1,649 enrolled
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00379041·1,158 enrolled
Non-Small Cell Lung Cancer9 trials
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown status·—·Phase 2·NCT00083083·250 enrolled
Show 6 more trials
Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
Completed·—·Phase 4·NCT03092986·60 enrolled
Hodgkin's Disease5 trials
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002462·615 enrolled
Show 2 more trials
Bladder Cancer4 trials
19 more indications
Bone Marrow Transplantation1 trial
Kidney Cancer1 trial
Malignant Mesothelioma1 trial
Cervical Cancer1 trial
Chemotherapy1 trial
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT00014274·238 enrolled
Ewing's Sarcoma1 trial
Langerhans Cell Histiocytosis1 trial
Transitional Cell Carcinoma1 trial
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00028756·285 enrolled
HIV infection1 trial
Neoadjuvant Chemotherapy1 trial
Metastatic Melanoma1 trial
Germ Cell Tumor1 trial
Glioma1 trial
Hodgkin Lymphoma1 trial
Renal Pelvis and Ureter Urothelial Carcinoma1 trial
Low Grade Astrocytoma1 trial
Stage III1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for vinblastine sulfate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details